SML0857
HQL 79
≥98% (HPLC)
别名:
4-Benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]-piperidine
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
room temp
SMILES string
[nH]1nnnc1CCCN2CCC(CC2)OC(c4ccccc4)c3ccccc3
InChI
1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26)
InChI key
TZQGXAHOROZEKN-UHFFFAOYSA-N
Biochem/physiol Actions
HQL 79 is an orally active anti-allergic agent that acts as an antagonist for histamine H1 receptors (H1R), eliciting anti-asthmatic effects. It interacts with prostaglandin (PG) D synthase (H-PGDS) in the catalytic region. It may be potential lead due to its H-PGDS inhibition to treat allergies.
HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthase, one of two synthases involved in the production of Prostaglandin D2 (PGD2) from arachidonic acid. PGD2 is a lipid signaling molecule, which activates two receptors, DP1 involved in centrally mediated processes such as sleep and pain and DP2 involved and inflammation. The two PGD synthases involved in its synthesis are lipocalin-type (L-PGDS) and hematopoietic (H-PDGS), which acts to form PGD2 in mast cells, Th2 cells, microglia, and other inflammatory cells/tissues. HQL-79 selectively inhibited the activity of recombinant H-PGDS with an IC50 of 6 μM and had almost no effect on COX-1, COX-2, m-PGES, or L-PGDS up to 300 μM. HQL-79 has anti-inflammatory activity in vitro and in vivo.
HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthase.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable